Profile: AtriCure Inc (ATRC.OQ)

ATRC.OQ on NASDAQ Stock Exchange Global Market

9.80USD
1 Aug 2013
Price Change (% chg)

$0.14 (+1.45%)
Prev Close
$9.66
Open
$9.69
Day's High
$9.90
Day's Low
$9.69
Volume
21,398
Avg. Vol
24,141
52-wk High
$10.00
52-wk Low
$5.90

Search Stocks

AtriCure, Inc., incorporated on October 31, 2000, is a medical device company. The Company develops, manufactures and sells cardiac surgical ablation systems designed to create lesions, or scars, in cardiac, or heart, tissue and devices for the exclusion of the left atrial appendage. The Company has two primary product lines for the ablation of cardiac tissue. Its primary product line, which accounts for a majority of its revenues is the AtriCure Synergy Ablation System, a bipolar ablation clamp system and related radiofrequency ablation devices. It also offers a cryoablation product line, which features reusable and disposable cryoablation devices. In addition, it offers the AtriClip Gillinov-Cosgrove Left Atrial Appendage System, or AtriClip system, which is designed to exclude the left atrial appendage.

In the United States, the Company primarily sells its products to medical centers through its direct sales force. AtriCure Europe, B.V., its wholly owned subsidiary, markets and sells its products throughout Europe, the Middle East and Africa (EMEA) primarily through distributors, while in Germany and Benelux region the Company sells directly to medical centers. The Company sells its products to other international distributors, primarily in Asia, South America and Canada.

AtriCure’s Synergy Ablation System and Related Radio-Frequency Ablation Devices

The Company’s synergy System and related radio-frequency ( RF) devices such as its multifunctional pens represent its primary product line. Its Synergy System and related RF devices are used in both open and minimally invasive procedures. The Company’s products include Isolator Synergy Bipolar Radio-Frequency Ablation Clamps, Ablation and Sensing Unit (ASU), AtriCure Switch Box (ASB) and Isolator Multifunctional Pens. The Company sells multiple configurations of its Isolator Synergy clamps. During the year ended December 31, 2011, the Company released its Isolator Synergy Access clamps in the United States, a new open-heart configuration featuring a pivoting clamp head. Its Isolator Synergy clamps are single-use disposables and have jaws that close in a parallel fashion.

The Company’s ASU is a power generator that uses its software and delivers bipolar RF energy. The ASU provides the RF energy necessary for its clamps, multifunctional pens and Coolrail linear ablation device. The Company’s ASB is a switch box, which provides the technology needed for the dual pulsing electrodes in its Isolator Synergy clamps, as well as the ability to connect and toggle between its multiple RF devices. Its Isolator multifunctional pen is a disposable RF device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing and stimulation and ablate cardiac tissue with the same device.

Cryoablation System

The Company’s cryoablation offering consists of a variety of reusable and disposable devices, which use cryothermy, or extreme cold, to ablate cardiac tissue. During 2011, the Company introduced its next generation cryo generator, cryoICE BOX. Its disposable cryoablation devices are used with its cryoablation generators and are being adopted by physicians for AF ablation treatment during certain open-heart procedures, for which physicians prefer cryoablation over RF ablation.

AtriClip System

The Company’s AtriClip system is designed to exclude the left atrial appendage by implanting the device during concomitant open surgical procedures from the outside of the heart, avoiding contact with the circulating blood pool, while eliminating blood flow between the left atrial appendage and the atria. During 2011, the AtriClip system was approved for use during a minimally invasive ablation procedure for patients enrolling in its DEEP AF clinical trial.

In addition, the Company also sells enabling technologies including its Lumitip dissector and MicroPace ORLab system. The Lumitip dissector is used by surgeons to separate tissues to provide access to key anatomical structures that are targeted for ablation. Its ORLab system is a stimulating, mapping and recording system when used with a mapping probe, enables physicians to confirm that the ablation lines being created are forming electrical barriers or lines of block.

The Company competes with Medtronic, Inc., St. Jude Medical, Inc., nContact, Inc. and Endoscopic Technologies, Inc. and Biosense Webster, Inc.

Company Address

AtriCure Inc

6217 Centre Park Drive
WEST CHESTER   OH   45069
P: +1513.7554100
F: +1513.7554108

Search Stocks